Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 84Ovarian Neoplasms 35Breast Neoplasms 32Lung Neoplasms 28Uterine Cervical Neoplasms 18Triple Negative Breast Neoplasms 15Fallopian Tube Neoplasms 15Carcinoma, Ovarian Epithelial 15Small Cell Lung Carcinoma 13Squamous Cell Carcinoma of Head and Neck 10Neuroblastoma 10Esophageal Neoplasms 10Esophageal Squamous Cell Carcinoma 8Central Nervous System Neoplasms 8Recurrence 7Head and Neck Neoplasms 6Endometrial Neoplasms 6Retinoblastoma 5Neoplasm Metastasis 5Brain Neoplasms 5Adenocarcinoma of Lung 5Neoplasms 4Melanoma 4Carcinoma, Squamous Cell 4Testicular Neoplasms 3Oligodendroglioma 3Medulloblastoma 3Lymphoma, Large B-Cell, Diffuse 3Hodgkin Disease 3Glioblastoma 3

Interventions

pembrolizumab 1Pemetrexed 1Cisplatin 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Nonsquamous Non-small Cell Lung Cancer × Carboplatin × Clear all
NCT04750083 2021-02-11

HX008 Plus Chemotherapy VS Pembrolizumab Plus Chemotherapy As the First-line Treatment in Participants With Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer

Taizhou Hanzhong biomedical co. LTD

Phase 2/3 Unknown
700 enrolled
Thoracic

Nonsquamous Non-small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡